Evidence map›Paper›PMID 42570464›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2026

Discovery of thienopyrimidine analog G-18 as a novel anti-trichomonal agent.

Yao Zhang, Bingqian Zhang, Daiqian Zhu, Xiaolong Fu, Fengxu Wu, Yanggen Hu, Jian Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yao ZhangDepartment of Human Parasitology, School of Basic Medical Sciences, School of Pharmaceutical Sciences and Institute of Medicinal Chemistry, Hubei University of Medicine, Shiyan, 442000, China.
Bingqian ZhangDepartment of Human Parasitology, School of Basic Medical Sciences, School of Pharmaceutical Sciences and Institute of Medicinal Chemistry, Hubei University of Medicine, Shiyan, 442000, China.
Daiqian ZhuDepartment of Human Parasitology, School of Basic Medical Sciences, School of Pharmaceutical Sciences and Institute of Medicinal Chemistry, Hubei University of Medicine, Shiyan, 442000, China.
Xiaolong FuDepartment of Human Parasitology, School of Basic Medical Sciences, School of Pharmaceutical Sciences and Institute of Medicinal Chemistry, Hubei University of Medicine, Shiyan, 442000, China.
Fengxu WuDepartment of Human Parasitology, School of Basic Medical Sciences, School of Pharmaceutical Sciences and Institute of Medicinal Chemistry, Hubei University of Medicine, Shiyan, 442000, China.
Yanggen HuDepartment of Human Parasitology, School of Basic Medical Sciences, School of Pharmaceutical Sciences and Institute of Medicinal Chemistry, Hubei University of Medicine, Shiyan, 442000, China. Electronic address: huyg@hbmu.edu.cn.
Jian LiDepartment of Human Parasitology, School of Basic Medical Sciences, School of Pharmaceutical Sciences and Institute of Medicinal Chemistry, Hubei University of Medicine, Shiyan, 442000, China. Electronic address: yxlijian@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trichomoniasis, caused by Trichomonas vaginalis, is the most prevalent nonviral sexually transmitted infection worldwide. The occurrence of treatment failure with metronidazole (MTZ) and the adverse effects of currently available nitroimidazoles underscore the necessity for novel therapeutic candidates. From a library of synthetic thienopyrimidine derivatives, G-18 was identified as a lead compound. G-18 exhibited potent anti-T. vaginalis activity against the tested T. vaginalis isolate, with a minimum inhibitory concentration (MIC) of 4 μg/mL and a half-maximal inhibitory concentration (IC

Indexed as

Antiprotozoal AgentsAntitrichomonal AgentsPyrimidinesTrichomonas vaginalisAnimalsHumansInhibitory Concentration 50MetronidazoleMicroscopy, Electron, ScanningMicroscopy, Electron, TransmissionParasitic Sensitivity TestsTrophozoitesAntiprotozoal AgentsAntitrichomonal AgentsMetronidazolePyrimidinesthienopyrimidineDrug resistanceMetronidazoleParasite viabilityThienopyrimidine derivativeTrichomonas vaginalisTrichomoniasisUltrastructural damage

Identifiers

PMID42570464
PMCPMC13485611

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.